TL;DR: A new study reveals that impaired cerebrovascular function—the brain’s ability to regulate blood flow—correlates strongly with Alzheimer’s symptoms, offering a potential non-invasive way to detect early cognitive decline. Alzheimer’s disease has long been framed as a problem of toxic protein accumulation: amyloid plaques and tau tangles strangling neurons into silence. But what if the …
TL;DR: Metformin’s glucose-lowering effect depends on a brain signaling pathway—it inhibits Rap1 in the hypothalamus, activating neurons that tell the liver to stop overproducing glucose. For decades, metformin has been the first-line drug for type 2 diabetes, working so reliably that millions take it daily. Yet its precise mechanism—how it actually lowers blood sugar—has remained …
TL;DR: When older adults face large balance challenges, their brains shift from relying on quick brainstem reflexes to slower cortical circuits—a shift that happens even in Parkinson’s disease, revealing a mechanistic window into age-related balance loss. Balance isn’t automatic. When you stumble forward or feel the ground shift, your nervous system launches a cascade of …
TL;DR: Fathers experience a protective period early postpartum (depression drops by 26%), but depression and stress surge at months 10-11, creating a 30-36% elevated risk when no one is screening for it. Perinatal psychiatry has a crisis of attention. Mothers are screened relentlessly. Fathers are largely invisible. Yet a groundbreaking Swedish national study reveals something …
TL;DR: Lecanemab, the first Alzheimer’s antibody to slow cognitive decline, works by activating immune cells called microglia through a specific immune signaling pathway, with the molecule SPP1/osteopontin playing a critical role in triggering the brain’s own cleanup machinery. When lecanemab was approved by the FDA, it sparked hope but also raised a fundamental question: how …
TL;DR: Researchers mapped how genes are regulated differently across six brain cell types in Alzheimer’s disease, discovering that excitatory neurons drive the most extensive regulatory disruptions—and identifying key hub genes like RPS27A that could become therapeutic targets. Alzheimer’s disease is a disease of broken communication. The brain doesn’t just lose cells—it loses control, as genes …
TL;DR: Untreated depression increases miscarriage risk by 34% across nearly 9 million women, but antidepressants reduce that risk to 24%—meaning the medication is safer than the disease during pregnancy. For decades, obstetricians have asked the wrong question about depression in pregnancy. They worried: Is the antidepressant dangerous? New data suggests a more sobering reality—the untreated …
TL;DR: A pesticide sprayed on US crops decades ago more than doubles your risk of Parkinson’s disease, and new research shows exactly how it damages dopamine neurons. You probably never heard of chlorpyrifos, but your neighborhood may have been sprayed with it. This common agricultural insecticide was applied to millions of acres across California and …
TL;DR: Researchers discovered a toxic interaction between two brain proteins—NMDAR and TRPM4—that drives neurodegeneration in Alzheimer’s disease, and a small molecule called FP802 that blocks this “death complex” and prevents cognitive decline in mice. Alzheimer’s disease devastates the brain through multiple pathways, but the exact triggering mechanisms remain frustratingly unclear. A new study in Molecular …
TL;DR: Using PET imaging to directly visualize AMPA receptors in the living human brain, researchers discovered that ketamine’s rapid antidepressant effect works by reshuffling these receptors across specific brain regions in patients with treatment-resistant depression — and where they go predicts who will respond to the drug. Nearly one in three people with depression fail …
